Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $1,065,000.00 in Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker sold 100,000 shares of the stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $10.65, for a total value of $1,065,000.00. Following the completion of the transaction, the chief operating officer now owns 896,869 shares of the company’s stock, valued at $9,551,654.85. This trade represents a 10.03 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Eric Venker also recently made the following trade(s):

• On Thursday, February 13th, Eric Venker sold 218,041 shares of Roivant Sciences stock. The shares were sold at an average price of $10.42, for a total transaction of $2,271,987.22.
• On Tuesday, January 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.28, for a total transaction of $1,128,000.00.
• On Monday, December 30th, Eric Venker sold 177,704 shares of Roivant Sciences stock. The shares were sold at an average price of $11.54, for a total transaction of $2,050,704.16.
• On Friday, December 27th, Eric Venker sold 176,900 shares of Roivant Sciences stock. The stock was sold at an average price of $11.82, for a total transaction of $2,090,958.00.
• On Friday, December 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $11.49, for a total value of $1,149,000.00.

Roivant Sciences Trading Down 1.5 %

Shares of NASDAQ:ROIV opened at $10.52 on Tuesday. The business has a fifty day simple moving average of $11.17 and a 200 day simple moving average of $11.60. Roivant Sciences Ltd. has a 1 year low of $9.76 and a 1 year high of $13.06. The firm has a market cap of $7.51 billion, a price-to-earnings ratio of -70.13 and a beta of 1.25.

Roivant Sciences (NASDAQ:ROIV) last posted its quarterly earnings results on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. On average, sell-side analysts forecast that Roivant Sciences Ltd. will post -0.92 EPS for the current year.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. Cantor Fitzgerald raised Roivant Sciences to a “strong-buy” rating in a research report on Thursday, January 30th. HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of Roivant Sciences in a research note on Tuesday, February 11th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $18.08.

Institutional Trading of Roivant Sciences

Institutional investors have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. bought a new position in shares of Roivant Sciences during the 4th quarter valued at $181,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Roivant Sciences by 4.5% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,411,466 shares of the company’s stock worth $28,528,000 after buying an additional 104,288 shares during the last quarter. Zimmer Partners LP bought a new position in Roivant Sciences during the fourth quarter valued at about $2,992,000. Vestal Point Capital LP acquired a new stake in shares of Roivant Sciences in the fourth quarter worth about $14,788,000. Finally, Vident Advisory LLC boosted its stake in shares of Roivant Sciences by 98.7% during the 4th quarter. Vident Advisory LLC now owns 32,039 shares of the company’s stock worth $379,000 after acquiring an additional 15,918 shares in the last quarter. 64.76% of the stock is currently owned by institutional investors and hedge funds.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.